TEMPUS AI, INC. CLASS A COMMON STOCK

NASDAQ: TEM (Tempus AI, Inc.)

Last update: yesterday, 12:28AM

66.52

-1.82 (-2.66%)

Previous Close 68.34
Open 69.00
Volume 13,606,182
Avg. Volume (3M) 12,962,611
Market Cap 11,829,850,112
Price / Sales 12.47
Price / Book 36.25
52 Weeks Range
30.77 (-53%) — 91.45 (37%)
Earnings Date 4 Aug 2025 - 19 Aug 2025
Profit Margin -88.27%
Operating Margin (TTM) -26.93%
Diluted EPS (TTM) -5.16
Quarterly Revenue Growth (YOY) 75.40%
Total Debt/Equity (MRQ) 262.96%
Current Ratio (MRQ) 1.71
Operating Cash Flow (TTM) -193.29 M
Levered Free Cash Flow (TTM) 54.30 M
Return on Assets (TTM) -43.89%

Market Trend

Short Term Medium Term
Industry Health Information Services (US) Bearish Mixed
Health Information Services (Global) Bearish Mixed
Stock Tempus AI, Inc. Bullish -

AIStockmoo Score

-0.2
Analyst Consensus 1.5
Insider Activity -3.5
Price Volatility -0.5
Technical Moving Averages 1.0
Technical Oscillators 0.5
Average -0.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TEM 12 B - - 36.25
HQY 9 B - 76.17 4.24
WAY 7 B - 316.62 2.10
RCM 6 B - - 2.14
PRVA 3 B - 191.25 4.07
WGS 3 B - - 7.10

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Sector Healthcare
Industry Health Information Services
Investment Style Small Growth
% Held by Insiders 43.27%
% Held by Institutions 38.06%

Ownership

Name Date Shares Held
Ark Investment Management Llc 31 Mar 2025 7,501,399
Nikko Asset Management Americas, Inc. 31 Mar 2025 4,260,553
Sumitomo Mitsui Trust Group, Inc. 31 Mar 2025 4,255,477
Nea Management Company, Llc 31 Mar 2025 2,615,979
Revolution Growth Management Company, Inc. 31 Mar 2025 1,467,565
52 Weeks Range
30.77 (-53%) — 91.45 (37%)
Price Target Range
60.00 (-9%) — 70.00 (5%)
High 70.00 (B of A Securities, 5.23%) Hold
70.00 (Piper Sandler, 5.23%) Hold
70.00 (Needham, 5.23%) Buy
Median 70.00 (5.23%)
Low 60.00 (BTIG, -9.80%) Buy
Average 67.00 (0.72%)
Total 3 Buy, 2 Hold
Avg. Price @ Call 57.84
Firm Date Target Price Call Price @ Call
B of A Securities 25 Jun 2025 70.00 (5.23%) Hold 65.47
20 May 2025 68.00 (2.22%) Hold 62.43
Piper Sandler 15 May 2025 70.00 (5.23%) Hold 62.60
Morgan Stanley 09 May 2025 65.00 (-2.29%) Buy 61.37
Needham 07 May 2025 70.00 (5.23%) Buy 58.76
24 Apr 2025 70.00 (5.23%) Buy 53.50
BTIG 21 Apr 2025 60.00 (-9.80%) Buy 40.98
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
LEFKOFSKY ERIC P - 69.61 -500,000 -34,802,500
PHELPS ERIK - 72.00 -51,317 -3,694,824
POLOVIN ANDREW - 72.00 -1,423 -102,456
Aggregate Net Quantity -552,740
Aggregate Net Value ($) -38,599,780
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 70.80
Name Holder Date Type Quantity Price Value ($)
LEFKOFSKY ERIC P Officer 18 Jun 2025 Automatic sell (-) 250,000 69.10 17,275,000
LEFKOFSKY ERIC P Officer 17 Jun 2025 Automatic sell (-) 250,000 70.11 17,527,500
PHELPS ERIK Officer 16 Jun 2025 Automatic sell (-) 51,317 72.00 3,694,824
POLOVIN ANDREW Officer 16 Jun 2025 Automatic sell (-) 1,423 72.00 102,456
Date Type Details
25 Jun 2025 Announcement Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
17 Jun 2025 Announcement Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
13 Jun 2025 Announcement Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
12 Jun 2025 Announcement Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
02 Jun 2025 Announcement Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
01 Jun 2025 Announcement Introducing Tempus One in the EHR with Integrated Guidelines
31 May 2025 Announcement Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
30 May 2025 Announcement Real-World Deployments Signal AI Healthcare Is Ready for Scale
30 May 2025 Announcement Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
28 May 2025 Announcement A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
28 May 2025 Announcement Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: TEM)
21 May 2025 Announcement Tempus to Present at the William Blair 45th Annual Growth Stock Conference
21 May 2025 Announcement Options Trading Now Available on Three Tradr ETFs: QBTX, TEMT and APPX
20 May 2025 Announcement Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
20 May 2025 Announcement From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
14 May 2025 Announcement Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
13 May 2025 Announcement Tradr Launches First Leveraged ETF on Tempus AI
13 May 2025 Announcement Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
12 May 2025 Announcement Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
06 May 2025 Announcement Tempus Reports First Quarter 2025 Results
05 May 2025 Announcement Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
05 May 2025 Announcement AI Healthcare Boom Gains Speed as Regulators and Innovators Align
01 May 2025 Announcement Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
29 Apr 2025 Announcement Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
28 Apr 2025 Announcement Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
25 Apr 2025 Announcement Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
24 Apr 2025 Announcement Tempus to Report First Quarter 2025 Financial Results on May 6
23 Apr 2025 Announcement Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
18 Apr 2025 Announcement Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
15 Apr 2025 Announcement Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
29 Mar 2025 Announcement Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria